415 related articles for article (PubMed ID: 23224737)
1. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
Dingemans AM; Mellema WW; Groen HJ; van Wijk A; Burgers SA; Kunst PW; Thunnissen E; Heideman DA; Smit EF
Clin Cancer Res; 2013 Feb; 19(3):743-51. PubMed ID: 23224737
[TBL] [Abstract][Full Text] [Related]
2. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.
Paz-Ares L; Hirsh V; Zhang L; de Marinis F; Yang JC; Wakelee HA; Seto T; Wu YL; Novello S; Juhász E; Arén O; Sun Y; Schmelter T; Ong TJ; Peña C; Smit EF; Mok TS
J Thorac Oncol; 2015 Dec; 10(12):1745-53. PubMed ID: 26743856
[TBL] [Abstract][Full Text] [Related]
3. A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
Zhou Q; Zhou CC; Chen GY; Cheng Y; Huang C; Zhang L; Xu CR; Li AW; Yan HH; Su J; Zhang XC; Yang JJ; Wu YL
Lung Cancer; 2014 Mar; 83(3):369-73. PubMed ID: 24440279
[TBL] [Abstract][Full Text] [Related]
4. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
Lind JS; Dingemans AM; Groen HJ; Thunnissen FB; Bekers O; Heideman DA; Honeywell RJ; Giovannetti E; Peters GJ; Postmus PE; van Suylen RJ; Smit EF
Clin Cancer Res; 2010 Jun; 16(11):3078-87. PubMed ID: 20395213
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Kelly RJ; Rajan A; Force J; Lopez-Chavez A; Keen C; Cao L; Yu Y; Choyke P; Turkbey B; Raffeld M; Xi L; Steinberg SM; Wright JJ; Kummar S; Gutierrez M; Giaccone G
Clin Cancer Res; 2011 Mar; 17(5):1190-9. PubMed ID: 21224376
[TBL] [Abstract][Full Text] [Related]
6. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
Lim SM; Cho BC; Kim SW; Kang SY; Heo DS; Kim HT; Lee DH; Kim DW; Jung M; Choi JH; Shim HS; Choi JR; Kim JH
Lung Cancer; 2016 Mar; 93():1-8. PubMed ID: 26898607
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Zappa F; Droege C; Betticher D; von Moos R; Bubendorf L; Ochsenbein A; Gautschi O; Oppliger Leibundgut E; Froesch P; Stahel R; Hess T; Rauch D; Schmid P; Mayer M; Crowe S; Brauchli P; Ribi K; Pless M;
Lung Cancer; 2012 Dec; 78(3):239-44. PubMed ID: 23009726
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
9. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
[TBL] [Abstract][Full Text] [Related]
10. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
11. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
Goldman JW; Shi P; Reck M; Paz-Ares L; Koustenis A; Hurt KC
Clin Lung Cancer; 2016 Jan; 17(1):80-4. PubMed ID: 26432508
[TBL] [Abstract][Full Text] [Related]
12. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
Horiike A; Takeuchi K; Uenami T; Kawano Y; Tanimoto A; Kaburaki K; Tambo Y; Kudo K; Yanagitani N; Ohyanagi F; Motoi N; Ishikawa Y; Horai T; Nishio M
Lung Cancer; 2016 Mar; 93():43-6. PubMed ID: 26898613
[TBL] [Abstract][Full Text] [Related]
14. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
Metro G; Chiari R; Duranti S; Siggillino A; Fischer MJ; Giannarelli D; Ludovini V; Bennati C; Marcomigni L; Baldi A; Giansanti M; Minotti V; Crinò L
Lung Cancer; 2012 Oct; 78(1):81-6. PubMed ID: 22770374
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sorafenib for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Wang WL; Tang ZH; Xie TT; Xiao BK; Zhang XY; Guo DH; Wang DX; Pei F; Si HY; Zhu M
Asian Pac J Cancer Prev; 2014; 15(14):5691-6. PubMed ID: 25081687
[TBL] [Abstract][Full Text] [Related]
16. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.
Camps C; Jantus-Lewintre E; Cabrera A; Blasco A; Sanmartín E; Gallach S; Caballero C; del Pozo N; Rosell R; Guijarro R; Sirera R
Lung Cancer; 2011 Jun; 72(3):365-9. PubMed ID: 21074889
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
Marabese M; Ganzinelli M; Garassino MC; Shepherd FA; Piva S; Caiola E; Macerelli M; Bettini A; Lauricella C; Floriani I; Farina G; Longo F; Bonomi L; Fabbri MA; Veronese S; Marsoni S; Broggini M; Rulli E
Oncotarget; 2015 Oct; 6(32):34014-22. PubMed ID: 26416458
[TBL] [Abstract][Full Text] [Related]
19. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
Riely GJ; Johnson ML; Medina C; Rizvi NA; Miller VA; Kris MG; Pietanza MC; Azzoli CG; Krug LM; Pao W; Ginsberg MS
J Thorac Oncol; 2011 Aug; 6(8):1435-7. PubMed ID: 21847063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
